3/5
11:02 am
ikt
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.